Trial record 4 of 22 for:    Open Studies | "Hernia, Diaphragmatic"

Gene Mutation and Rescue in Human Congenital Diaphragmatic Hernia (CDH)

This study is currently recruiting participants.
Verified August 2012 by Massachusetts General Hospital
Sponsor:
Collaborator:
Children's Hospital Boston
Information provided by (Responsible Party):
Patricia Donahoe, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01098929
First received: March 31, 2010
Last updated: August 13, 2012
Last verified: August 2012
  Purpose

The purpose of this study is to generate information about the hereditary basis of Congenital Diaphragmatic Hernia (CDH) and abnormal lung development. Our long-term goal, is to identify ways to pre-treat babies in utero with effective but safe drugs to speed up lung development before birth.


Condition
Congenital Diaphragmatic Hernia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Gene Mutation and Rescue in Human Congenital Diaphragmatic Hernia

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • identify genes associated w/CDH [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    We have ongoing studies for additional 5 years, we hope to identify more genes associated w/CDH in hopes of improving outcomes for individuals with this condition.


Biospecimen Retention:   Samples With DNA

blood, urine, skin biopsy, paraffin blocks


Estimated Enrollment: 1000
Study Start Date: July 2002
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Individuals with CDH
Any individual with Congenital Diaphragmatic Hernia (CDH)

Detailed Description:

The purpose of this study is to generate information about the hereditary basis of Congenital Diaphragmatic Hernia (CDH) and abnormal lung development. Our long-term goal is to identify ways to pre-treat babies in utero with effective but safe drugs to speed up lung development before birth.

Congenital Diaphragmatic Hernia (CDH) is a frequent and often fatal developmental condition that appears to be caused by diverse, including genetic, factors. This project uses a combination of clinical, molecular biological, and developmental strategies to identify genetic causes of this anomaly.

Ongoing projects at Massachusetts General Hospital include identification of novel genes contributing to lung and diaphragm development in: a) rodent models (using laser capture, microdissection, expression arrays, and statistical and bioinformatics analyses); and b) human kindreds having multiple family members affected with CDH (using linkage analysis and exome sequencing approaches).

In the portion of the project based at Children's Hospital Boston, ongoing projects include: a) continued recruitment of a cohort of patients with CDH who are carefully phenotyped for entry into a structurally sound database; b) collection and storage of biological materials belonging to the phenotyped cohort of patients; c) next-generation sequencing on candidate genes; and d) molecular cytogenetic studies such as Comparative Genomic Hybridization and subtelomeric FISH.

Over 350 patients with CDH, and their parents, have been recruited to date. Efforts are ongoing to triple this number. The knowledge generated by uncovering genes responsible for CDH will provide the foundation for future efforts to develop effective interventions for this potentially devastating syndrome.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Any individuals with Congenital Diaphragmatic Hernia (CDH)

Criteria

Inclusion Criteria:

  • Index cases will be any patient with congenital diaphragmatic hernia or eventration, regardless of additional anomalies
  • Family member (i.e. mother, father, grandparent, sibling, or child) of index case with congenital diaphragmatic hernia or eventration

Exclusion Criteria:

  • No parent or guardian is available to give consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01098929

Contacts
Contact: Anna Frangulov, B.S. 617 355 2555 CDHResearchStudy@tch.harvard.edu
Contact: Meaghan Russell, PhD(c), MPH 617 726 0828 mrussell@partners.org

Locations
United States, Massachusetts
Meaghan Russell Recruiting
Boston, Massachusetts, United States, 02114
Contact: Meaghan Russell, PhD(c), MPH     617-726-5057     mrussell@partners.org    
Contact: Anna Frangulov, B.S.     617 355 2555     CDHResearchStudy@tch.harvard.edu    
Principal Investigator: Patricia Donahoe, M.D.            
Sponsors and Collaborators
Massachusetts General Hospital
Children's Hospital Boston
Investigators
Principal Investigator: Patricia Donahoe, M.D. Mass General Hospital
Principal Investigator: Jay Wilson, M.D. Children's Hospital Boston
  More Information

No publications provided

Responsible Party: Patricia Donahoe, MD, Principal Investigator & Program Director, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01098929     History of Changes
Other Study ID Numbers: 05-07-105R
Study First Received: March 31, 2010
Last Updated: August 13, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
bioinformatics
genetic
genetics
CDH
Congenital Diaphragmatic Hernia

Additional relevant MeSH terms:
Hernia
Hernia, Diaphragmatic
Hernia, Hiatal
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on May 16, 2013